NCT05905497View on ClinicalTrials.gov

The Study of Bemnifosbuvir in Healthy Japanese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 26, 2023

Primary Completion Date

May 19, 2023

Study Completion Date

May 19, 2023

Conditions
Healthy Volunteer Study
Interventions
DRUG

Bemnifosbuvir (BEM)

BEM administered BID for 4 days and QD on Day 5 (9 consecutive doses)

Trial Locations (1)

90630

Atea Study Site, Cypress

Sponsors
All Listed Sponsors
lead

Atea Pharmaceuticals, Inc.

INDUSTRY

NCT05905497 - The Study of Bemnifosbuvir in Healthy Japanese Subjects | Biotech Hunter | Biotech Hunter